The Subject Expert Committee (SEC) has recommended phase 1 clinical trials of Reliance Life Sciences’ vaccine candidate against Covid-19. The proposed jab comprises two doses, and is based on a recombinant protein platform, as per reports.
Reliance Life Sciences, owned by Mukesh Ambani-led business group, if given a nod from the Drugs Controller General India, the country’s top drugs regulator, can begin the first phase of clinical trials for its vaccine candidate.
While Reliance Sciences itself is a testing centre for Covid-19, the exercise will be conducted at 10 sites, including those in Delhi, Maharashtra, Tamil Nadu and Andhra Pradesh. Phase 1 lasts for nearly two months, or 58 days, and is conducted to detect the highest number of doses that most patients can tolerate, as per reports. The DCGI has thus far granted Emergency Use Authorisation (EUA) to six vaccines, of which two are indigenous while the rest are foreign-made.